
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay is a highly promising medical technology company that offers advanced non-invasive treatments for mental health disorders through its Deep TMS platform. With a profitable recurring revenue model and investments in expanding their reach, the company is well-positioned in the TMS market and is also venturing into new treatment options like psilocybin therapy. Although facing competition and execution risks, their strong financials and track record make them a promising investment for the future.
Bears say
BrainsWay is in a growing market with a well-defined customer base and recurring revenue model, but its long-term growth is dependent on execution of clinical trials and reimbursement for novel indications. Despite its strong position in the US market, the company faces significant risks, including delays in clinical trials, failure to expand reimbursement, and potential dilution. These risks, coupled with a projected sales multiple-driven valuation of $17 per share, make the current stock outlook negative for financial analysts.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares